

CorMedix Inc.  
Form 8-K  
August 14, 2014

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 14, 2014

CORMEDIX INC.  
(Exact Name of  
Registrant as  
Specified in  
Charter)

Delaware (State or Other Jurisdiction of Incorporation)	001-34673  (Commission File Number)	20-5894890  (IRS Employer Identification No.)
--	--	--

745 Rt. 202-206,  
Suite 303,  
Bridgewater, NJ 08807  
(Address of  
Principal  
Executive  
Offices) (Zip  
Code)

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former  
Address, If Changed Since  
Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Edgar Filing: CorMedix Inc. - Form 8-K

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 8.01. Other Events.

On August 14, 2014, CorMedix issued a press release announcing that the U.S. Food and Drug Administration agreed with the design of our pivotal Phase III protocol for Neutrolin® in hemodialysis patients, and our entry into a business collaboration in South Korea.

A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.	Description
----------------	-------------

<u>99.1</u>	Press release dated August 14, 2014.
-------------	--------------------------------------

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: August 14, 2014

By: /s/ Randy Milby  
Name: Randy Milby  
Title: Chief Executive Officer

3

---